Schöffski P et al. |
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. |
2011 |
Cancer Chemother. Pharmacol. |
pmid:21465314
|
Malik G et al. |
Aziridines from intramolecular alkene aziridination of sulfamates: reactivity toward carbon nucleophiles. application to the synthesis of spisulosine and its fluoro analogue. |
2011 |
J. Org. Chem. |
pmid:21812488
|
Xu K et al. |
A highly anti-selective asymmetric Henry reaction catalyzed by a chiral copper complex: applications to the syntheses of (+)-spisulosine and a pyrroloisoquinoline derivative. |
2012 |
Chemistry |
pmid:22907874
|
Massard C et al. |
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. |
2012 |
Invest New Drugs |
pmid:22215532
|
Vilar E et al. |
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. |
2012 |
Invest New Drugs |
pmid:20820909
|
Calder ED et al. |
Preparation of anti-vicinal amino alcohols: asymmetric synthesis of D-erythro-sphinganine, (+)-spisulosine, and D-ribo-phytosphingosine. |
2013 |
J. Org. Chem. |
pmid:23795558
|
Abad JL et al. |
Straightforward access to spisulosine and 4,5-dehydrospisulosine stereoisomers: probes for profiling ceramide synthase activities in intact cells. |
2013 |
J. Org. Chem. |
pmid:23679346
|
Byun HS et al. |
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. |
2013 |
Medchemcomm |
pmid:24396570
|
Wei N et al. |
Altered sphingoid base profiles in type 1 compared to type 2 diabetes. |
2014 |
Lipids Health Dis |
pmid:25305670
|
Kowluru A |
Deoxysphingolipids: β-cell, beware of these new kids on the block. |
2014 |
Diabetes |
pmid:24651803
|